GFAP and Parkinson disease: In a study focused on the sexual bias of PD, the injection of -methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) caused an increase in the GFAP mRNA levels only at the early stages in murine males, compared to females who displayed an increase in both the early and late time frames.